News

Filter

Current filters:

Eli LillyCymbalta

1 to 9 of 16 results

Most-used agents in US bipolar disorder treatment sector; report

Most-used agents in US bipolar disorder treatment sector; report

24-10-2014

Through analysis of US longitudinal patient-level claims data, Bristol-Myers Squibb and Otsuka’s Abilify…

AbilifyBristol-Myers SquibbCymbaltaDainippon Sumitomo PharmaEli LillyGlaxoSmithKlineLamotrigineLatudaMarkets & MarketingNeurologicalOtsukaPharmaceuticalUSA

Eli Lilly hit by patent expirations on Cymbalta and Evista as third-qtr profit drops of 58%

Eli Lilly hit by patent expirations on Cymbalta and Evista as third-qtr profit drops of 58%

23-10-2014

US drug major Eli Lilly reported third quarter 2014 results that showed how badly the company has been…

CymbaltaEli LillyEli Lilly and CompanyEvistaFinancialPharmaceuticalUnited StatesUSA

Eli Lilly exceeds expectations with third quarter results

Eli Lilly exceeds expectations with third quarter results

24-10-2013

US pharma major Eli Lilly has announced financial results for the third quarter of 2013. Despite the…

AlimtaAmyvidAxironCialisCymbaltaEffientEli LillyEvistaFinancialForteoHumalogNorth AmericaPharmaceuticalStratteraTrajentaZyprexa

Eli Lilly records higher than expected earnings in 2nd-qtr results

24-07-2013

US drug major Eli Lilly's (NYSE: LLY) recorded higher than expected earnings as growth in key products…

AlimtaCialisCymbaltaEffientEli LillyEvistaFinancialForteoHumalogNorth AmericaPharmaceuticalStratteraZyprexa

1 to 9 of 16 results

COMPANY SPOTLIGHT

Menarini

Back to top